Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metvix PDT vs cryotherapy for actinic keratoses (non-face/scalp)
2004-000700-41Phase 3Completed
- Sponsor
- Galderma
- Start
- Sep 2004
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by Galderma. Primary endpoint: Lesion response rate at week 24. Started Sep 2004; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2004-000700-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000700-41.